Aprepitant as add-on to standard antiemetic regimen for concurrent chemoradiotherapy induced nausea vomiting in head and neck cancer

Table 2 Baseline demographic & disease characteristics of the two study groups, n (%)/mean ± SD/median (range)

Characteristics	Group A, n = 43	Group B, n = 43	P value
Age (years)	59.93 ± 9.18	55.12 ± 10.38	0.02
Males	39 (90.7)	38 (88.4)	0.73
BMI (kg/m2)	22.42 ± 1.11	22.84 ± 1.08	0.08
ECOG performance
0	5 (11.62)	6 (13.95)
1	38 (88.4)	37 (86)	0.75
Tumor stage
Stage III	19 (44.19)	17 (39.53)	0.67
Stage IV A	23 (53.49)	24 (55.81)	0.83
Stage IV B	1 (2.33)	2 (4.65)	0.56
Tumor location
Oral cavity	2 (4.65)	8 (18.60)	0.04
Oropharynx	34 (79.07)	26 (60.47)	0.06
Hypopharynx	0 (0.00)	2 (4.65)	0.16
Larynx	7 (16.28)	7 (16.28)	1.00
History of smoking
No. of smokers	42 (97.67)	39 (90.70)	0.17
No. of years of smoking	30 (1-55)	25 (0.5-40)	0.01
No. of bidis smoked	20 (5-40)	20 (2-50)	0.83
No. of hukka smokers	2 (4.65)	0 (0.00)
History of alcohol	34 (79.07)	27 (62.79)	0.1
Presence of comorbidities	9 (20.93)	4 (9.30)	0.1

ECOG: Eastern Cooperative Oncology Group; 0: Fully active, no restrictions; 1: Restricted in strenuous activity, ambulatory; BMI: Body mass index.